The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 21, 2015

Filed:

Jul. 08, 2009
Applicants:

Emanuel F. Petricoin, Iii, Gainesville, VA (US);

Lance A. Liotta, Bethesda, MD (US);

Virginia Espina, Rockville, MD (US);

Julia D. Wulfkuhle, Columbia, MD (US);

Inventors:

Emanuel F. Petricoin, III, Gainesville, VA (US);

Lance A. Liotta, Bethesda, MD (US);

Virginia Espina, Rockville, MD (US);

Julia D. Wulfkuhle, Columbia, MD (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A01N 43/48 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2006.01); A61K 31/517 (2006.01); G01N 1/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); A61K 31/517 (2013.01); A61K 39/39558 (2013.01); C12Q 1/6841 (2013.01); C12Q 1/6886 (2013.01); G01N 1/30 (2013.01); G01N 33/54366 (2013.01); G01N 33/574 (2013.01); G01N 33/57415 (2013.01); A61K 2039/505 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); G01N 2033/57403 (2013.01); G01N 2333/71 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.


Find Patent Forward Citations

Loading…